Sanofi ADR
USUSDSanofi ADR (MI:1SAN) — Biotechnology: Pharmaceutical Preparations. Počet burz, na kterých se obchodují akcie společnosti: 6. Na této stránce — cena a graf, dividendy, největší akcionáři a historie počtu akcií.
O společnosti
- Web
- sanofi.com
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sídlo
- PARIS, France
- Generální ředitel
- Paul Hudson
- Zaměstnanci
- 106 566
- Založena
- 2004
- Na burze od
- 24.07.2006 (MI:1SAN)
- Akcie v oběhu
- 1.22 mld. k 2025-12-31
- Volně obchodovatelné akcie
- 2.16 mld.
- Tržní kapitalizace
- 98.67 mld. USD
- Insideři
- 0%
- Instituce
- 8.02%
- Odvětví (SIC)
- Pharmaceutical Preparations
- Právní forma
- QVPB
- ISIN
- FR0000120578
- LEI
- 549300E9PC51EN656011
- Výplatní poměr
- 0%
- FCF
- 10.8 mld. EUR
- Dluh
- 18.7 mld. EUR1.0 r. FCF
- Dividendová řada
- 23 r.
- Zisk, FCF a vyplacené dividendy — za 12 měsíců do 31.12.2025 (poslední zpráva společnosti).
Popis
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Burzy a tickery
| Burza | Ticker | Měna | Cena | Typ |
|---|---|---|---|---|
| US USA Stocks | SNYNF OTC | USD | 78.99 -1.19% | kmenové akcie |
| LSE London Stock Exchange | 0O59 IOB | EUR | 71.63 +0.72% | kmenové akcie |
| MI Borsa Italiana (Milan) | 1SAN doplňková | EUR | 71.64 +0.90% | kmenové akcie |
| PA Euronext Paris | SAN hlavní | EUR | 71.52 +0.83% | kmenové akcie |
| VI Vienna Stock Exchange | SANO doplňková | EUR | 71.3 +1.03% | kmenové akcie |
| XETRA Xetra | SNW doplňková | EUR | 71.78 -1.21% | kmenové akcie |
Dividendy
Sanofi ADR (1SAN) vyplácí dividendy jednou ročně. Za posledních 12 měsíců bylo vyplaceno 4.12 EUR na akcii (platby: 1). To je asi 5.75% současné ceny akcií. Na základě platební historie se očekává další datum ex-dividendy kolem 04.05.2027. Roky nepřerušených dividend: 23.
| Ex-dividendový den | Výplata | Částka | % | Typ | Ticker |
|---|---|---|---|---|---|
| 2026-05-05 | 2026-05-07 | 4.1200 EUR | 5.8/5.8 % | roční | MI:1SAN |
| 2025-05-12 | 2025-05-14 | 3.9200 EUR | 5.5/5.5 % | roční | MI:1SAN |
| 2024-05-13 | — | 3.7600 EUR | 5.2/10.2 % | roční | MI:1SAN |
| 2023-05-30 | — | 3.5600 EUR | 5.0/5.0 % | roční | MI:1SAN |
| 2022-05-06 | — | 3.3300 EUR | 4.6/4.6 % | roční | MI:1SAN |
Zprávy tento týden
Zatím žádné zprávy z webu společnosti.
Největší držitelé
| Držitel | Podíl | Akcie | Datum zprávy |
|---|---|---|---|
| Dodge & Cox Inc. | 10.54% | 28.09 mil. | 2026-06-30 |
| Dodge & Cox Funds-Dodge… | 7.84% | 20.9 mil. | 2026-06-30 |
| Morgan Stanley | 4.02% | 10.7 mil. | 2026-06-30 |
| Fisher Asset Management,… | 3.99% | 10.63 mil. | 2026-06-30 |
| Bank of America Corporat… | 3% | 8.01 mil. | 2026-06-30 |
| Invesco Ltd. | 2.55% | 6.8 mil. | 2026-06-30 |
| JPMORGAN CHASE & CO | 2.47% | 6.57 mil. | 2026-06-30 |
| Mondrian Investment Part… | 2.07% | 5.52 mil. | 2026-06-30 |
| Brandes Investment Partn… | 1.55% | 4.14 mil. | 2026-06-30 |
| AIM Sector Funds (Invesc… | 1.51% | 4.03 mil. | 2026-04-30 |
| Federated Hermes, Inc. | 1.44% | 3.85 mil. | 2026-06-30 |
| Boston Partners | 1.44% | 3.84 mil. | 2026-06-30 |
| VANGUARD STAR FUNDS-Vang… | 1.31% | 15.85 mil. | 2026-07-31 |
| Putnam ETF Trust-Putnam… | 1.26% | 3.36 mil. | 2026-05-31 |
| VANGUARD TAX-MANAGED FUN… | 0.87% | 10.53 mil. | 2026-06-30 |
| iShares Trust-iShares Co… | 0.67% | 8.11 mil. | 2026-08-31 |
| Dodge & Cox Funds-Dodge… | 0.63% | 1.67 mil. | 2026-06-30 |
| AMERICAN MUTUAL FUND | 0.59% | 1.58 mil. | 2026-06-30 |
| American Century Capital… | 0.37% | 976 561 | 2026-06-30 |
| Bridge Builder Trust-Bri… | 0.36% | 967 100 | 2026-06-30 |
| Fidelity Concord Street… | 0.35% | 4.24 mil. | 2026-07-31 |
| VanEck ETF Trust-VanEck… | 0.35% | 938 561 | 2026-08-31 |
| Dodge & Cox Funds-Dodge… | 0.33% | 4.04 mil. | 2026-06-30 |
| iShares Trust-iShares MS… | 0.32% | 3.89 mil. | 2026-08-31 |
| Capital World Growth & I… | 0.3% | 3.67 mil. | 2026-06-30 |
| -Victory Pioneer Core Eq… | 0.3% | 799 487 | 2026-06-30 |
| Fidelity Covington Trust… | 0.3% | 797 184 | 2026-08-31 |
| NEW PERSPECTIVE FUND | 0.29% | 3.56 mil. | 2026-06-30 |
| Federated Hermes Eqy. Fd… | 0.29% | 3.48 mil. | 2026-07-31 |
| Bridge Builder Trust-Bri… | 0.29% | 3.44 mil. | 2026-06-30 |
| Pacer Advisors, Inc. | 0.1% | 1.16 mil. | 2026-06-30 |
| Generali Investments Cee… | 0% | 29 339 | 2026-06-30 |
| Paradigm Asset Managemen… | 0% | 19 200 | 2026-06-30 |
| Gamma Investing LLC | 0% | 58 | 2026-06-30 |
| L'Oréal | — | — | — |
